BR0208526A - Formulação farmacêutica de liberação controlada, e métodos para produzir a mesma e para preparar um sal de citrato de macrolìdeo - Google Patents
Formulação farmacêutica de liberação controlada, e métodos para produzir a mesma e para preparar um sal de citrato de macrolìdeoInfo
- Publication number
- BR0208526A BR0208526A BR0208526-7A BR0208526A BR0208526A BR 0208526 A BR0208526 A BR 0208526A BR 0208526 A BR0208526 A BR 0208526A BR 0208526 A BR0208526 A BR 0208526A
- Authority
- BR
- Brazil
- Prior art keywords
- macrolide
- citrate salt
- preparing
- methods
- controlled release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
"FORMULAçãO FARMACêUTICA DE LIBERAçãO CONTROLADA E MéTODOS PARA PRODUZIR A MESMA E PARA PREPARAR UM SAL DE CITRATO DE MACROLìDEO". é descrita uma formulação farmacêutica de macrolídeo de liberação controlada oral. Em uma versão preferida, a formulação compreende um sal de citrato de um macrolídeo preferido, claritromicina. Também descritos são os métodos para preparar, isolar e caracterizar sal de citrato solúvel e estável de macrolídeos e seu uso em todas as formas de dosagem sólida dos macrolídeos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1019DE2001 | 2001-10-01 | ||
IN1018DE2001 | 2001-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0208526A true BR0208526A (pt) | 2004-08-10 |
Family
ID=26324885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0208526-7A BR0208526A (pt) | 2001-10-01 | 2002-10-01 | Formulação farmacêutica de liberação controlada, e métodos para produzir a mesma e para preparar um sal de citrato de macrolìdeo |
Country Status (9)
Country | Link |
---|---|
US (1) | US6642276B2 (pt) |
EP (1) | EP1302205B1 (pt) |
JP (1) | JP2003212757A (pt) |
AT (1) | ATE291922T1 (pt) |
BR (1) | BR0208526A (pt) |
CA (1) | CA2405918A1 (pt) |
DE (1) | DE60203461T2 (pt) |
DK (1) | DK1302205T3 (pt) |
PT (1) | PT1302205E (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
WO2004100880A2 (en) * | 2003-05-06 | 2004-11-25 | Nirmal Mulye | Controlled release formulation of erythromycin derivatives |
EP2529730A1 (en) | 2003-06-16 | 2012-12-05 | ANDRX Pharmaceuticals LLC. | Oral sustained-release composition |
WO2005004919A2 (en) * | 2003-07-02 | 2005-01-20 | Eurand, Inc. | Extended release systems for macrolide antibiotics |
AU2004258953B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
US8425936B2 (en) | 2003-07-21 | 2013-04-23 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
JP2006528189A (ja) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質産物、その使用法および製剤 |
US20050049209A1 (en) * | 2003-08-06 | 2005-03-03 | Chen Andrew Xian | Pharmaceutical compositions for delivering macrolides |
CA2535177A1 (en) | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
AU2004264356B2 (en) | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
WO2005023184A2 (en) | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
CA2538064C (en) | 2003-09-15 | 2013-12-17 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
US20050084540A1 (en) * | 2003-10-17 | 2005-04-21 | Indranil Nandi | Taste masking antibiotic composition |
US8168228B2 (en) * | 2003-10-17 | 2012-05-01 | Sandoz Ag | Antibiotic clarithromycin micropellet compositions |
US20050101547A1 (en) * | 2003-11-06 | 2005-05-12 | Sadatrezaei Mohsen | Stabilized azithromycin composition |
EP1732518A1 (en) * | 2004-03-24 | 2006-12-20 | Lupin Ltd. | Clarithromycin extended release formulation |
JP2007530692A (ja) * | 2004-04-01 | 2007-11-01 | テバ ファーマシューティカル インダストリーズ リミティド | 6−メルカプトプリンの改良された製剤 |
US8188067B2 (en) | 2004-04-01 | 2012-05-29 | Teva Pharmaceutical Industries Ltd. | Formulations of 6-mercaptopurine |
EP1771158A4 (en) | 2004-07-02 | 2008-03-12 | Advancis Pharmaceutical Corp | TABLET FOR PULSED DELIVERY |
WO2006085497A1 (ja) * | 2005-02-09 | 2006-08-17 | Kissei Pharmaceutical Co., Ltd. | 口腔内崩壊錠 |
US20070087056A1 (en) * | 2005-08-09 | 2007-04-19 | Claudia Guthmann | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility |
US20070087055A1 (en) * | 2005-10-14 | 2007-04-19 | David Jan | Directly compressible extended release alprazolam formulation |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US20070202164A1 (en) * | 2006-02-28 | 2007-08-30 | Hutchison Medipharma Enterprises Limited | Andrographis Extract Formulations |
WO2007126039A1 (ja) * | 2006-04-28 | 2007-11-08 | Shionogi & Co., Ltd. | マクロライド系抗生物質の被覆製剤 |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
EP2030613A1 (en) * | 2007-08-17 | 2009-03-04 | Abbott GmbH & Co. KG | Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics |
EP2110130A1 (en) * | 2008-04-18 | 2009-10-21 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical use of 6-mercaptopurine |
CN101624412B (zh) * | 2008-07-10 | 2012-07-04 | 刘力 | 大环内酯类衍生物及其制备和用途 |
EP2283824B1 (en) | 2009-07-30 | 2017-04-19 | Special Products Line S.p.A. | Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin |
JP2013180961A (ja) * | 2012-02-29 | 2013-09-12 | Astellas Pharma Inc | Ws727713含有固形製剤 |
EP2671571A1 (en) | 2012-06-05 | 2013-12-11 | Sanovel Ilac Sanayi ve Ticaret A.S. | Controlled-release formulations of clarithromycin |
CN103776945A (zh) * | 2014-01-16 | 2014-05-07 | 扬子江药业集团南京海陵药业有限公司 | 罗红霉素胶囊的质量控制方法 |
WO2017066619A1 (en) | 2015-10-16 | 2017-04-20 | Teva Pharmaceutical Industries Ltd. | Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine |
CN105997929A (zh) * | 2016-06-23 | 2016-10-12 | 南京华宽信息咨询中心 | 一种罗红霉素胶囊及其制备方法 |
CN106580903B (zh) * | 2016-11-17 | 2019-12-13 | 江苏豪森药业集团有限公司 | 罗红霉素缓释药物组合物 |
CN109248155B (zh) * | 2018-09-27 | 2020-08-11 | 北京鑫开元医药科技有限公司 | 一种罗红霉素胶囊及其制备工艺 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0188040B1 (en) * | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
US5457111A (en) * | 1991-09-05 | 1995-10-10 | Abbott Laboratories | Macrocyclic immunomodulators |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US5750510A (en) * | 1997-04-04 | 1998-05-12 | Abbott Laboratories | 3-descladinose-2,3-anhydroerythromycin derivatives |
US6551616B1 (en) * | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
JPH10335732A (ja) * | 1997-06-02 | 1998-12-18 | Toshiba Microelectron Corp | レーザ用制御回路および制御方法 |
US6239112B1 (en) * | 1998-07-09 | 2001-05-29 | Merial, Inc. | Water miscible macrolide solutions |
IT1303671B1 (it) * | 1998-07-28 | 2001-02-23 | Nicox Sa | Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio |
SI20150A (sl) * | 1999-02-19 | 2000-08-31 | Lek, Tovarna Farmacevtskih In | Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina |
TR200000054A2 (tr) * | 2000-01-05 | 2001-08-21 | Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ | Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları. |
-
2002
- 2002-09-30 CA CA002405918A patent/CA2405918A1/en not_active Abandoned
- 2002-09-30 US US10/261,564 patent/US6642276B2/en not_active Expired - Fee Related
- 2002-10-01 JP JP2002324526A patent/JP2003212757A/ja active Pending
- 2002-10-01 DK DK02256823T patent/DK1302205T3/da active
- 2002-10-01 DE DE60203461T patent/DE60203461T2/de not_active Expired - Lifetime
- 2002-10-01 AT AT02256823T patent/ATE291922T1/de active
- 2002-10-01 PT PT02256823T patent/PT1302205E/pt unknown
- 2002-10-01 BR BR0208526-7A patent/BR0208526A/pt active Search and Examination
- 2002-10-01 EP EP02256823A patent/EP1302205B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6642276B2 (en) | 2003-11-04 |
EP1302205B1 (en) | 2005-03-30 |
DE60203461D1 (de) | 2005-05-04 |
DK1302205T3 (da) | 2005-08-08 |
EP1302205A1 (en) | 2003-04-16 |
ATE291922T1 (de) | 2005-04-15 |
CA2405918A1 (en) | 2003-04-01 |
US20030077325A1 (en) | 2003-04-24 |
JP2003212757A (ja) | 2003-07-30 |
PT1302205E (pt) | 2005-06-30 |
DE60203461T2 (de) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0208526A (pt) | Formulação farmacêutica de liberação controlada, e métodos para produzir a mesma e para preparar um sal de citrato de macrolìdeo | |
HUP0101237A1 (hu) | Elnyújtott kioldódású gyógyszerkészítmények | |
AR028574A1 (es) | Mascara de administracion de farmacos para animales | |
MXPA03003895A (es) | Formulaciones de hidrocodona de liberacion controlada. | |
DE69936002D1 (de) | Angepasster löffel zur oralen medikamenten-verabreichung | |
AU2002357012A1 (en) | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof | |
EE05400B1 (et) | Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks | |
NO20025879L (no) | Acylfenylureaderivater, fremgangsmåter for fremstilling derav og deres anvendelse som legemiddel | |
AR028285A1 (es) | Medicamentos intracorporeos para tratamiento fotodinamico de enfermedad | |
EP1246608A4 (en) | PHARMACEUTICAL PREPARATIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES WITH LOW WATER SOLUBILITY | |
DK1345910T3 (da) | Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf | |
HU0102039D0 (en) | Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby | |
NO20020976D0 (no) | Retarderte, orale, farmasöytiske administreringsformer | |
NO20020811D0 (no) | Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler | |
EE05081B1 (et) | Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid | |
ATE317260T1 (de) | Pharmazeutische formulierungen mit platinderivaten | |
IL159217A0 (en) | An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine | |
MXPA03002569A (es) | Formulaciones de liberacion controlada para administracion oral. | |
ATA59499A (de) | Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung | |
DK1004592T3 (da) | Nye erythromycinderivater, deres fremstilling og deres anvendelse som medikamenter | |
PT1455761E (pt) | Composições farmacêuticas para a administração oral de heparina ou seus derivados | |
DE60134414D1 (de) | 4-pyrimidinamine derivate, pharmazeutische zusammenstellungen und verwandte methoden | |
ATE409474T1 (de) | Tryptamin-derivative und analoge verbindungen, und pharmazeutische formulationen daraus | |
GT200100033A (es) | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina. | |
HUP0500958A2 (en) | 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/7048 (2006.01), A61P 31/00 (2006.01) |